
An update from Genmab ( ($GMAB) ) is now available. Genmab is an international biotechnology company focused on antibody medicines for cancer and other serious diseases. Its research spans bispecific
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GMAB | Genmab | 50.60 | 20.15 | 66.17% |
| Name | Price | % Change | |
|---|---|---|---|
| $50.60 | +66.17% |

An update from Genmab ( ($GMAB) ) is now available. Genmab is an international biotechnology company focused on antibody medicines for cancer and other serious diseases. Its research spans bispecific

Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Genmab (GMAB) to $56 from $57 and keeps an Equal Weight rating on the shares. The firm adjusted estimates

Genmab ( ($GMAB) ) has provided an update. On November 12, 2026, Genmab reported that board members Martin Schultz and Mijke Zachariasse sold 617 and 351 Genmab shares, respectively, at

Genmab ( ($GMAB) ) has shared an announcement. Genmab A/S is engaged in medical research, production and sale of related products, and related business. Its Articles of Association state that

The latest update is out from Genmab ( ($GMAB) ). Genmab is an international biotechnology company developing innovative antibody medicines for cancer and other serious diseases. Its work includes bispecific

An update from Genmab ( ($GMAB) ) is now available. Genmab A/S disclosed that CEO Jan G. J. van de Winkel sold 22,000 shares on November 10, 2026, at an

Genmab ( ($GMAB) ) has provided an announcement. On November 10, 2026, Genmab announced a share-capital increase of 164,828 shares following the exercise of employee warrants. The shares were subscribed

BTIG lowered the firm’s price target on Bicara Therapeutics (BCAX) to $37 from $39 and keeps a Buy rating on the shares after its Q3 results. The firm states the

Genmab (Otc) (($GMAB)) has held its Q3 earnings call. Read on for the main highlights of the call. Genmab’s earnings call carried a strongly positive tone, with broad revenue growth,

Genmab ( ($GMAB) ) has shared an announcement. Genmab A/S is a biotechnology company developing antibody-based medicines focused on cancer, with products including epcoritamab, Rina-S and petosemtamab. Its global business
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Reiterated | Oct 29, 2026 | ||||
| buy | Assigned | Oct 26, 2026 | ||||
| buy | Reiterated | Aug 7, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 24, 2027TBA | $30.75B | $0.21 | $1.25B | -0.23 | 42.85 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.